Clinical Trial UpdatesFulcrum Therapeutics reported positive results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). Th...
Clinical Trial UpdatesFoghorn Therapeutics announced updates on its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader selectively binds and ...
Clinical Trial UpdatesDrs. Lanman and Ament performed the first known combined implantation of the MOTUS total joint replacement device and the TOPS™ System at adjacent lum...
Clinical Trial Updates4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...
Clinical Trial UpdatesEyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIA trial evaluating DURAVYU™ for wet age-related macular degenerati...
Clinical Trial UpdatesExelixis announced positive results from the Phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with immune checkpoint inhibitors fo...
Clinical Trial UpdatesExelixis announced detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in...
Clinical Trial UpdatesExact Sciences announced the presentation of ten abstracts at the 2025 ASCO Annual Meeting, showcasing new data on its Oncodetect MRD test, multi-canc...
Clinical Trial UpdatesEnvoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...
Clinical Trial UpdatesEnterra Medical has launched the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) for treating chronic ...
Clinical Trial UpdatesEndogenex announced positive 48-week results from its REGENT-1 clinical study at Digestive Disease Week 2025. The study evaluated the safety and effic...
Clinical Trial UpdatesEncoded Therapeutics announced preclinical data for its AAV9 microRNA (miRNA) gene therapy candidate targeting SCN9A (NaV1.7) for chronic pain. The da...
Private by design. Speaks your language. Proven at scale
